--- title: "The Ultimate Shred Stack — Retatrutide + Tesamorelin" description: "A complete retatrutide + tesamorelin stack protocol for body recomposition. Dosing, timing, bloodwork, cost breakdown, and the clinical data behind targeting" lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Article", "headline": "The Ultimate Shred Stack — Retatrutide + Tesamorelin Protocol for Body Recomposition", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/bhglogo.png" } }, "datePublished": "2026-04-10", "dateModified": "2026-04-10", "mainEntityOfPage": "https://www.bodyhackguide.co/blog/ultimate-shred-stack-retatrutide-tesamorelin-protocol", "wordCount": 6800, "timeRequired": "PT18M" }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Can you stack retatrutide with tesamorelin?", "acceptedAnswer": { "@type": "Answer", "text": "Retatrutide and tesamorelin operate on completely separate receptor systems with no pharmacological overlap. Retatrutide targets GLP-1, GIP, and glucagon receptors while tesamorelin activates GHRH receptors. No clinical trial has tested this combination, but the mechanistic logic supports co-administration." } }, { "@type": "Question", "name": "What is the best peptide stack for body recomposition?", "acceptedAnswer": { "@type": "Answer", "text": "A retatrutide plus tesamorelin stack targets recomposition from two angles: retatrutide drives total fat loss through triple receptor agonism while tesamorelin selectively reduces visceral fat at a 25:1 ratio over subcutaneous fat and preserves lean mass via GH-mediated anabolic signaling." } }, { "@type": "Question", "name": "How much does a retatrutide tesamorelin stack cost per month?", "acceptedAnswer": { "@type": "Answer", "text": "Research-grade peptide cost runs approximately $150-300 per month depending on dosing. Retatrutide at 3-4mg weekly costs roughly $80-150/month and tesamorelin at 1mg daily five days per week costs approximately $70-150/month from research peptide suppliers." } }, { "@type": "Question", "name": "Does retatrutide cause muscle loss?", "acceptedAnswer": { "@type": "Answer", "text": "GLP-1 monotherapy typically causes significant lean tissue loss. STEP-1 DXA data showed roughly 40% of weight lost on semaglutide was lean tissue. Retatrutide's glucagon component may improve metabolic flexibility, and pairing it with tesamorelin's GH-mediated anabolic signal is designed to offset muscle loss." } }, { "@type": "Question", "name": "How much visceral fat does tesamorelin reduce?", "acceptedAnswer": { "@type": "Answer", "text": "Pooled Phase 3 data showed tesamorelin reduced visceral adipose tissue by 15.4% while subcutaneous fat decreased only 0.6%, yielding a roughly 25:1 selectivity ratio. In non-HIV obese adults, 12-month treatment reduced VAT by 35 cm squared with no significant change in subcutaneous fat." } }, { "@type": "Question", "name": "Can peptides help with fatty liver?", "acceptedAnswer": { "@type": "Answer", "text": "Both compounds in this stack have demonstrated hepatic fat reduction. Retatrutide reduced liver fat by 86% at 12mg over 48 weeks. Tesamorelin reduced hepatic fat by 37% over 12 months with 35% NAFLD resolution versus 4% on placebo." } }, { "@type": "Question", "name": "What is the difference between retatrutide and tirzepatide for recomp?", "acceptedAnswer": { "@type": "Answer", "text": "Tirzepatide is a dual GLP-1/GIP agonist. Retatrutide adds a third receptor, glucagon, which drives hepatic lipid oxidation and energy expenditure. Phase 2 data showed 24.2% weight loss at 12mg with curves still descending at 48 weeks, compared to tirzepatide's roughly 20-22% in similar timeframes." } }, { "@type": "Question", "name": "How long should you run a retatrutide tesamorelin cycle?", "acceptedAnswer": { "@type": "Answer", "text": "Minimum effective cycle is 8 weeks. Standard protocol runs 12 weeks. Advanced users may extend to 16 weeks with a tesamorelin break every 6-8 weeks. Retatrutide effects compound over time as weight loss curves had not plateaued at 48 weeks in Phase 2 trials." } }, { "@type": "Question", "name": "What bloodwork do you need for a peptide stack?", "acceptedAnswer": { "@type": "Answer", "text": "Baseline panel should include CBC, CMP, lipid panel, fasting glucose and insulin for HOMA-IR, HbA1c, thyroid panel, IGF-1, testosterone, liver enzymes, and CRP. IGF-1 monitoring is mandatory with tesamorelin. Repeat at weeks 4, 8, and 12." } }, { "@type": "Question", "name": "Does tesamorelin raise blood sugar?", "acceptedAnswer": { "@type": "Answer", "text": "Tesamorelin can cause a transient fasting glucose increase of 7-9 mg/dL in the first weeks that typically resolves by 6-12 months. In strong responders with 8% or greater VAT reduction, fasting glucose actually decreases. The combination with retatrutide's HOMA2-IR reduction of 69.3% strongly favors net glucose improvement." } } ] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "lastReviewed": "2026-04-10", "specialty": { "@type": "MedicalSpecialty", "name": "PharmacologySpecialty" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Blog", "item": "https://www.bodyhackguide.co/blog" }, { "@type": "ListItem", "position": 3, "name": "Ultimate Shred Stack", "item": "https://www.bodyhackguide.co/blog/ultimate-shred-stack-retatrutide-tesamorelin-protocol" } ] }, { "@context": "https://schema.org", "@type": "Article", "headline": "The Ultimate Shred Stack — Retatrutide + Tesamorelin Protocol for Body Recomposition", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/bhglogo.png" } }, "datePublished": "2026-04-10", "dateModified": "2026-04-10", "mainEntityOfPage": "https://www.bodyhackguide.co/blog/ultimate-shred-stack-retatrutide-tesamorelin-protocol", "wordCount": 6800, "timeRequired": "PT18M" }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Can you stack retatrutide with tesamorelin?", "acceptedAnswer": { "@type": "Answer", "text": "Retatrutide and tesamorelin operate on completely separate receptor systems with no pharmacological overlap. Retatrutide targets GLP-1, GIP, and glucagon receptors while tesamorelin activates GHRH receptors. No clinical trial has tested this combination, but the mechanistic logic supports co-administration." } }, { "@type": "Question", "name": "What is the best peptide stack for body recomposition?", "acceptedAnswer": { "@type": "Answer", "text": "A retatrutide plus tesamorelin stack targets recomposition from two angles: retatrutide drives total fat loss through triple receptor agonism while tesamorelin selectively reduces visceral fat at a 25:1 ratio over subcutaneous fat and preserves lean mass via GH-mediated anabolic signaling." } }, { "@type": "Question", "name": "How much does a retatrutide tesamorelin stack cost per month?", "acceptedAnswer": { "@type": "Answer", "text": "Research-grade peptide cost runs approximately $150-300 per month depending on dosing. Retatrutide at 3-4mg weekly costs roughly $80-150/month and tesamorelin at 1mg daily five days per week costs approximately $70-150/month from research peptide suppliers." } }, { "@type": "Question", "name": "Does retatrutide cause muscle loss?", "acceptedAnswer": { "@type": "Answer", "text": "GLP-1 monotherapy typically causes significant lean tissue loss. STEP-1 DXA data showed roughly 40% of weight lost on semaglutide was lean tissue. Retatrutide's glucagon component may improve metabolic flexibility, and pairing it with tesamorelin's GH-mediated anabolic signal is designed to offset muscle loss." } }, { "@type": "Question", "name": "How much visceral fat does tesamorelin reduce?", "acceptedAnswer": { "@type": "Answer", "text": "Pooled Phase 3 data showed tesamorelin reduced visceral adipose tissue by 15.4% while subcutaneous fat decreased only 0.6%, yielding a roughly 25:1 selectivity ratio. In non-HIV obese adults, 12-month treatment reduced VAT by 35 cm squared with no significant change in subcutaneous fat." } }, { "@type": "Question", "name": "Can peptides help with fatty liver?", "acceptedAnswer": { "@type": "Answer", "text": "Both compounds in this stack have demonstrated hepatic fat reduction. Retatrutide reduced liver fat by 86% at 12mg over 48 weeks. Tesamorelin reduced hepatic fat by 37% over 12 months with 35% NAFLD resolution versus 4% on placebo." } }, { "@type": "Question", "name": "What is the difference between retatrutide and tirzepatide for recomp?", "acceptedAnswer": { "@type": "Answer", "text": "Tirzepatide is a dual GLP-1/GIP agonist. Retatrutide adds a third receptor, glucagon, which drives hepatic lipid oxidation and energy expenditure. Phase 2 data showed 24.2% weight loss at 12mg with curves still descending at 48 weeks, compared to tirzepatide's roughly 20-22% in similar timeframes." } }, { "@type": "Question", "name": "How long should you run a retatrutide tesamorelin cycle?", "acceptedAnswer": { "@type": "Answer", "text": "Minimum effective cycle is 8 weeks. Standard protocol runs 12 weeks. Advanced users may extend to 16 weeks with a tesamorelin break every 6-8 weeks. Retatrutide effects compound over time as weight loss curves had not plateaued at 48 weeks in Phase 2 trials." } }, { "@type": "Question", "name": "What bloodwork do you need for a peptide stack?", "acceptedAnswer": { "@type": "Answer", "text": "Baseline panel should include CBC, CMP, lipid panel, fasting glucose and insulin for HOMA-IR, HbA1c, thyroid panel, IGF-1, testosterone, liver enzymes, and CRP. IGF-1 monitoring is mandatory with tesamorelin. Repeat at weeks 4, 8, and 12." } }, { "@type": "Question", "name": "Does tesamorelin raise blood sugar?", "acceptedAnswer": { "@type": "Answer", "text": "Tesamorelin can cause a transient fasting glucose increase of 7-9 mg/dL in the first weeks that typically resolves by 6-12 months. In strong responders with 8% or greater VAT reduction, fasting glucose actually decreases. The combination with retatrutide's HOMA2-IR reduction of 69.3% strongly favors net glucose improvement." } } ] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "lastReviewed": "2026-04-10", "specialty": { "@type": "MedicalSpecialty", "name": "PharmacologySpecialty" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Blog", "item": "https://www.bodyhackguide.co/blog" }, { "@type": "ListItem", "position": 3, "name": "Ultimate Shred Stack", "item": "https://www.bodyhackguide.co/blog/ultimate-shred-stack-retatrutide-tesamorelin-protocol" } ] } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fblog%2Fultimate-shred-stack-retatrutide-tesamorelin-protocol) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) [Home](/)/ [Blog](/blog)/ Ultimate Shred Stack Pillar Protocol 20 PMIDs 18 min read April 10, 2026 # The Ultimate Shred Stack Retatrutide + Tesamorelin The body recomposition protocol that targets visceral fat while preserving muscle. Every claim backed by clinical data. Retatrutide Triple GLP-1/GIP/Glucagon Agonist 28.7% weight loss · Phase 3 Tesamorelin GHRH Analog · FDA Approved 25:1 visceral ratio · +1.3kg lean mass C BioChonch Research Editor · BodyHackGuide Why the Scale Lies Jump to section For research and educational purposes only. Not medical advice. Nothing here is a prescription. Run your bloodwork and talk to a doctor before starting anything. You can lose 30 pounds and still look like hell in the mirror. I've seen it happen too many times in this community to pretend otherwise. Guy drops a chunk of weight on semaglutide, steps on the scale feeling proud, takes his shirt off and realizes he just melted a bunch of muscle along with the fat. Skinny-fat with a smaller waist. Visceral fat still wrapped around his liver. Face looks like it aged five years. That's the weight loss trap most people fall into and nobody warns you about it. The stack I'm walking you through today fixes that specific problem. Retatrutide — the triple agonist that just posted a 28.7% weight loss result in Phase 3, the most powerful weight loss compound ever tested in humans — paired with tesamorelin , the only FDA-approved compound that specifically hunts visceral fat while preserving muscle. Two compounds, two completely different pathways, zero overlap. This isn't a "lose weight fast" post. This is the recomp protocol that targets the fat that's actually killing you (visceral), keeps your muscle (GH axis), and remodels your metabolism from the inside out. Every claim in here has a PMID. Every dose has a source. Every number you see on the calculators below comes from actual clinical trial data. Let's get into it. ## Why the Scale Lies to You About Your Actual Health You can lose 30 pounds and still look like hell in the mirror. You can hit your goal weight and still have elevated liver enzymes, high CRP, and insulin resistance that's quietly seeding metabolic disease. The scale doesn't distinguish between the fat that matters and the fat that doesn't — and that distinction is everything. There are two fundamentally different types of body fat, and your body treats them very differently. Subcutaneous fat is the fat you can pinch — it sits between your skin and muscle. It's cosmetically annoying but metabolically mostly harmless. It stores energy, provides insulation, and beyond a certain point it's just extra padding. Visceral fat is the one that will kill you. It wraps around your organs — liver, pancreas, intestines — and it's not just sitting there passively. Visceral adipose tissue is metabolically active. It pumps out inflammatory cytokines (TNF-alpha, IL-6), drives insulin resistance directly through portal vein delivery of free fatty acids to the liver, and seeds non-alcoholic fatty liver disease. This is why the concept of TOFI — Thin Outside, Fat Inside — exists. You can be normal weight with a BMI of 22 and still have dangerous levels of visceral fat silently driving metabolic dysfunction. Standard weight loss approaches reduce both types of fat proportionally. That's the default. Caloric restriction, cardio, even GLP-1 drugs — they don't preferentially target visceral over subcutaneous. You can drop 30 pounds on semaglutide and find your liver enzymes and CRP are still elevated because the visceral compartment didn't come off fast enough relative to total weight lost. And there's a bigger problem with GLP-1 monotherapy: it eats muscle. The STEP-1 trial DXA data showed that approximately 40% of weight lost on semaglutide was lean tissue. Not fat — muscle, bone mineral density, everything that isn't adipose. Tirzepatide performs somewhat better at roughly 25% lean tissue loss, but that's still a quarter of your hard-earned muscle disappearing alongside the fat. This stack attacks both problems simultaneously. Retatrutide drives total fat loss through triple receptor agonism — GLP-1, GIP, and glucagon — creating a deeper caloric deficit and enhanced lipid oxidation beyond what any dual agonist can achieve. Tesamorelin targets visceral fat specifically at a roughly 25:1 selectivity ratio over subcutaneous fat while simultaneously preserving lean body mass through GH-mediated anabolic signaling. That's the difference between weight loss and recomposition. Weight loss is a number on a scale. Recomposition is changing what your body is made of — less visceral fat, more functional muscle, better metabolic markers. The scale might not move as dramatically, but the DXA scan, the bloodwork, and the mirror tell a completely different story. ## Retatrutide — The Triple Agonist Nobody Saw Coming Retatrutide (LY3437943, Eli Lilly) is the first triple GLP-1/GIP/glucagon receptor agonist to reach advanced clinical development. While semaglutide hits one receptor and tirzepatide hits two, retatrutide activates all three — and that third receptor is the one that changes the entire equation. ### Why the Glucagon Receptor Matters Insulin is the storage hormone. Glucagon is the release hormone. They're the yin and yang of metabolic regulation. Semaglutide and tirzepatide primarily make you eat less through GLP-1 mediated appetite suppression and GIP-mediated satiety signaling. That's powerful, but it's only half the equation. Retatrutide makes you eat less and burn more. The glucagon receptor component drives hepatic lipid oxidation — your liver starts mobilizing and burning its own fat stores. It increases energy expenditure. It enhances metabolic flexibility, meaning your body becomes better at switching between glucose and fat as fuel sources. This is why retatrutide's weight loss numbers are consistently ahead of anything else in the pipeline. ### The Clinical Data Phase 2 (Jastreboff et al., _New England Journal of Medicine_, 2023; [PMID: 37366315](https://pubmed.ncbi.nlm.nih.gov/37366315)): 338 adults with obesity, 48 weeks of treatment. The 12mg dose produced a 24.2% mean weight reduction . Response rates were extraordinary — 100% of participants achieved at least 5% weight loss, 93% hit 10% or more, 83% reached 15% or more. And critically, the weight loss curves had not plateaued at 48 weeks. They were still descending. Phase 3 TRIUMPH-4 (December 2025): 28.7% mean weight loss at 68 weeks, translating to an average of 71.2 pounds lost. TRANSCEND-T2D-1 (March 2026): In type 2 diabetes patients, HbA1c dropped 2.0 percentage points with 36.6 pounds lost over 40 weeks. Retatrutide is not FDA approved . It is currently in Phase 3 clinical trials. The projected NDA filing is late 2026 to early 2027, with commercial launch estimated for mid-to-late 2027 at the earliest. Any current use involves research-grade peptides outside of clinical trials. ### The Liver Fat Story A prespecified substudy analyzed retatrutide's impact on hepatic steatosis (Sanyal et al., _Nature Medicine_, 2024; [PMID: 38858523](https://pubmed.ncbi.nlm.nih.gov/38858523)). The results were remarkable: 86% reduction in liver fat at the 12mg dose over 48 weeks. 93% of participants reached normal hepatic fat levels (below 5%). HOMA2-IR dropped 69.3%, fasting insulin fell 70.9%, adiponectin increased 99.3%, and beta-hydroxybutyrate rose 181% — indicating a massive shift toward fat oxidation as a primary fuel source. ### Pharmacokinetics Retatrutide has a half-life of approximately 6 days (Urva et al., _The Lancet_, 2022; [PMID: 36354040](https://pubmed.ncbi.nlm.nih.gov/36354040)), supporting once-weekly dosing. Single-dose pharmacodynamic effects persist for up to 43 days, meaning the compound has a long tail of activity even after discontinuation. Steady state is reached within 4-5 weeks of consistent weekly dosing. [**Source retatrutide (BHG-3R) →** BHG Labs (common ownership with BodyHackGuide; we earn a commission on purchases through our links). Use code REDDIT for 10% off. See BHG Labs → ](https://bhglabs.co/product/bhg-3r-10mg/?ref=zmgqyxku&coupon=BHG20) ## Tesamorelin — The Visceral Fat Assassin Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). Rather than injecting exogenous growth hormone directly, tesamorelin stimulates your pituitary gland to release growth hormone in natural pulsatile patterns — the way your body is designed to produce it. It was FDA approved in November 2010 under the brand name Egrifta for the treatment of HIV-associated lipodystrophy — a condition where antiretroviral drugs cause abnormal visceral fat accumulation. It is the only FDA-approved drug specifically indicated as a visceral fat reducer. ### Phase 3 Data — The 25:1 Ratio Pooled Phase 3 data (Falutz et al., _Journal of Clinical Endocrinology & Metabolism_, 2010; [PMID: 20554713](https://pubmed.ncbi.nlm.nih.gov/20554713)) included 806 patients over 26 weeks. Visceral adipose tissue (VAT) decreased by 15.4% . Subcutaneous adipose tissue (SAT) decreased by just 0.6% — which was not statistically significant. That gives you a roughly 25:1 selectivity ratio for visceral over subcutaneous fat. Lean body mass increased by 1.2-1.3 kg. Tesamorelin doesn't just burn visceral fat — it preserves and slightly builds muscle tissue simultaneously. ### Why Visceral-Specific? The mechanism behind this selectivity is receptor density. Visceral adipose tissue has significantly higher GH and IGF-1 receptor density compared to subcutaneous fat depots. When tesamorelin triggers a GH pulse, visceral tissue is disproportionately exposed to the lipolytic signal. The fat that's hardest to reach with diet and exercise is the fat most responsive to this specific pathway. ### Beyond HIV — Data in General Obesity A critical study for this stack's rationale is Makimura et al. (_JCEM_, 2012; [PMID: 23015655](https://pubmed.ncbi.nlm.nih.gov/23015655)): 60 obese adults without HIV, 12 months of treatment. VAT decreased by 35 cm² with no significant change in subcutaneous fat. But the downstream metabolic effects were equally important — improved carotid intima-media thickness (a cardiovascular risk marker), reduced CRP (systemic inflammation), and improved triglycerides. ### Liver Fat Reduction Stanley et al. (_Lancet HIV_, 2019; [PMID: 31611038](https://pubmed.ncbi.nlm.nih.gov/31611038)) ran a 12-month randomized controlled trial examining tesamorelin's effect on hepatic fat. Results: 37% reduction in hepatic fat , with 35% of tesamorelin patients achieving NAFLD resolution compared to just 4% on placebo. Fibrosis progression occurred in only 10.5% of tesamorelin patients versus 37.5% on placebo. ### IGF-1 Response and Monitoring Tesamorelin increases IGF-1 levels by approximately 81-108 ng/mL at the 2mg daily dose and roughly 117% above baseline at 1mg daily (Baker et al.; [PMID: 22869065](https://pubmed.ncbi.nlm.nih.gov/22869065)). Target range is 50-100% above your individual baseline . If IGF-1 exceeds 350 ng/mL, reduce the dose. If it exceeds 400 ng/mL, stop tesamorelin and recheck in 4 weeks. ### Timing and Administration Tesamorelin has a plasma half-life of just 26-38 minutes. Each injection triggers a single endogenous GH pulse that peaks within 15-30 minutes and returns to baseline within 2-3 hours. This makes timing critical: inject in the evening, fully fasted, 30-60 minutes before bed, and at least 2 hours after your last meal. Growth hormone release is suppressed by insulin and glucose, so a fasted state maximizes the GH pulse amplitude. [**Source tesamorelin (BHG-2T) →** BHG Labs (common ownership with BodyHackGuide; we earn a commission on purchases through our links). Use code REDDIT for 10% off. See BHG Labs → ](https://bhglabs.co/product/bhg-2t-10mg/?ref=zmgqyxku&coupon=BHG20) ## Why the Stack Works — Two Pathways, Zero Overlap These two compounds operate on completely separate receptor systems. There is no competition, no antagonism, no shared metabolic pathway. They attack body composition from two entirely different angles that complement rather than interfere with each other. ### The Retatrutide Axis GLP-1 + GIP + glucagon receptor activation drives appetite suppression, hepatic lipid oxidation, enhanced metabolic flexibility, increased energy expenditure, and improved insulin sensitivity. This creates the caloric deficit and the metabolic environment for fat mobilization. Retatrutide is the catabolic driver — it makes your body release and burn stored fat. ### The Tesamorelin Axis GHRH receptor activation triggers pulsatile endogenous GH release, which drives IGF-1 production. This pathway provides visceral-selective lipolysis, lean mass preservation, and cognitive enhancement through GH/IGF-1 signaling. Tesamorelin is the anabolic signal — it tells your body to burn visceral fat specifically while protecting (and slightly building) muscle tissue. ### The Recomp Math Retatrutide creates the caloric deficit and drives total fat loss. Tesamorelin provides the anabolic signal that preserves lean tissue during that deficit. In a typical aggressive cut without pharmacological support, you might lose 3 pounds of muscle for every 7 pounds of fat. With this stack, the theoretical ratio shifts dramatically — more fat loss, less (potentially no) lean tissue loss, and preferential reduction of the most metabolically dangerous fat depot. ### The Glucose Question One legitimate concern with stacking: tesamorelin can cause a transient fasting glucose increase of 7-9 mg/dL in the first weeks of treatment (Stanley et al., 2014; [PMID: 25038357](https://pubmed.ncbi.nlm.nih.gov/25038357)). This typically resolves by 6-12 months. More importantly, in strong responders — those achieving 8% or greater VAT reduction — fasting glucose actually _decreases_ ([PMID: 22495074](https://pubmed.ncbi.nlm.nih.gov/22495074)). When you factor in retatrutide's 69.3% reduction in HOMA2-IR, the net effect on glucose metabolism strongly favors improvement. No clinical trial has tested this combination. The mechanistic logic is sound — separate receptor systems, complementary pathways, no known interaction points. But combined safety and efficacy data does not exist. This is a research protocol based on mechanistic reasoning, not an evidence-based clinical recommendation. ## The Protocol — Dosing, Timing, Cycle Length ### Retatrutide Dosing Retatrutide is dosed weekly at 1-4mg with a slow titration to minimize GI side effects. Subcutaneous injection, rotate injection sites, Sunday evening preferred for scheduling consistency. Weeks Dose Notes 1-4 1 mg/week Starting dose — assess GI tolerance 5-8 2 mg/week First escalation — most tolerability issues appear here 9-12 3-4 mg/week Target dose — hold at 3mg if 4mg causes significant GI distress Reconstitution: Add 1 mL bacteriostatic water per 10 mg vial to yield a concentration of 10 mg/mL. For a 2 mg dose, draw 0.20 mL (20 units on an insulin syringe). Store reconstituted vial refrigerated, use within 30 days. ### Tesamorelin Dosing Tesamorelin is dosed at 1 mg daily, 5 days on / 2 days off (5 mg total per week). Evening administration, fully fasted, 30-60 minutes before bed, minimum 2 hours after last meal. Subcutaneous injection in the abdomen. Reconstitution: Add 3 mL bacteriostatic water per 10 mg vial to yield a concentration of 3.33 mg/mL. For a 1 mg dose, draw 0.30 mL (30 units on an insulin syringe). Reconstituted tesamorelin is less stable than retatrutide — use within 7 days and keep refrigerated at all times. ### Cycle Length - 8 weeks minimum — enough time for retatrutide to reach full titration and tesamorelin to establish consistent GH pulsing - 12 weeks standard — full titration plus 4-8 weeks at target dose, sufficient for meaningful visceral fat reduction and metabolic marker improvement - 16 weeks advanced — for those with significant visceral fat burden. Take a tesamorelin break (2 weeks off) every 6-8 weeks to allow IGF-1 to normalize and prevent receptor desensitization ## Recomp Calculator Use this calculator to estimate your projected body composition changes based on starting stats, protocol duration, and adherence level. These projections are based on published clinical trial data extrapolated to stack protocols. ## Body Recomposition Projection Estimate fat loss, muscle gain & waist reduction over your protocol Current Weight200 lbs Body Fat20% Waist36 in Training Frequency Sedentary2-3x4-5x6+ Protocol Duration 8 weeks12 weeks16 weeks Projected Results — 12 Weeks Projected Weight 192.9lbs Projected BF% 17.9% Projected Waist 34.6in Total Fat Lost 7.1 lbs Body Fat Reduction 2.1% drop Waist Reduction 1.4 in Visceral Fat Reduction 29% Muscle Mass Change +3% Weight Change \-7.1 lbs Projections are estimates based on documented community results and clinical trial extrapolation. Individual results vary. This is not a guarantee. ### Visceral Fat Reduction Timeline Projected change over a 16-week protocol Before Week 0: Baseline Waist: 36.0 in After Week 12: -30% visceral fat Waist: 34.5 in Week 0 Week 12 Week 16 30% Visceral fat 34.5" Waist 12wk Duration ## Dosing Schedule Visualizer Interactive weekly schedule showing exactly when to inject each compound, when to do bloodwork, and how the titration progresses over the full cycle. ### Weekly Dosing Schedule Weeks 1-4Weeks 5-8Weeks 9-12 Retatrutide 1 mg / week Tesamorelin 1 mg / day (5x) Mon 1 mg Tue 1 mg Wed 1 mg Thu 1 mg Fri 1 mg Sat OFF Sun 1 mg Mon Tesa 1 mg Tue Tesa 1 mg Wed Tesa 1 mg Thu Tesa 1 mg Fri Tesa 1 mg Sat OFF Rest day Sun Reta 1 mg Retatrutide (GLP-1/GIP/Glucagon) Tesamorelin (GHRH analog) OFF Rest day Tap any day for timing details ## Cost Breakdown One of the most common questions is whether this stack is affordable outside of a clinical trial setting. Research-grade peptides are significantly cheaper than pharmaceutical equivalents, but the total cost includes more than just the compounds — you need bacteriostatic water, syringes, alcohol swabs, sharps disposal, and bloodwork at minimum. Use the calculator below to estimate your total protocol cost. ## Stack Cost Calculator ### Your Inputs Retatrutide price / vial $ Tesamorelin price / vial $ Reta weekly dose (mg) Tesa weekly dose (mg) Protocol duration (weeks) 8 wk12 wk16 wk Include supplies (~$7.50/wk) ### Cost Breakdown Retatrutide vials needed 3 Tesamorelin vials needed 6 * * * Retatrutide cost $300.00 Tesamorelin cost $390.00 Supplies cost $90.00 * * * Total (12 wk) $780.00 Est. weekly cost $65.00 Treatment Monthly Cost 8-Week Cost Your stack $282.00 $520.00 Wegovy (self-pay) $349.00 $698.00 Wegovy (list price) $1,350.00 $2,700.00 Zepbound (self-pay) $349.00 - $499.00 $698.00 - $998.00 Egrifta SV (brand tesa) $3,085.00 $6,170.00 [Get Retatrutide (RC-3R) at RCHQ](/go/rchq-retatrutide?utm_source=blog&utm_medium=inline&utm_campaign=ultimate-shred-stack&utm_content=cost-calc-reta)[Get Tesamorelin at RCHQ](/go/rchq-tesamorelin?utm_source=blog&utm_medium=inline&utm_campaign=ultimate-shred-stack&utm_content=cost-calc-tesa) [**Save 10% with code REDDIT →** Shop BHG Labs — common ownership with BodyHackGuide; we earn a commission on purchases through our links. Order now → ](https://bhglabs.co/?ref=zmgqyxku&coupon=BHG20) ## Bloodwork You Need to Run Running this stack without bloodwork is irresponsible. Tesamorelin directly raises IGF-1 levels, and retatrutide dramatically shifts metabolic markers. You need objective data to confirm the stack is doing what it should and to catch any issues early. ### Baseline Panel (Before Starting) - CBC — complete blood count - CMP — comprehensive metabolic panel (kidney, electrolytes) - Lipid panel — total cholesterol, LDL, HDL, triglycerides - Fasting glucose + fasting insulin — calculate HOMA-IR - HbA1c — 3-month average blood sugar - Thyroid panel — TSH, free T3, free T4 - IGF-1 — mandatory baseline for tesamorelin monitoring - Testosterone — total and free (GH axis can affect sex hormones) - Liver enzymes — ALT, AST, GGT (especially important given liver fat targeting) - CRP — high-sensitivity C-reactive protein (inflammatory marker) ### Week 4 — Mini Panel - IGF-1 — confirm tesamorelin is working and levels are in target range - Fasting glucose — check for tesamorelin-related glucose elevation - Fasting insulin — paired with glucose for HOMA-IR reassessment ### Week 8 — Full Repeat Run the entire baseline panel again. By week 8 you should be at or near full retatrutide dose and tesamorelin will have been running for 8 weeks. This is your first comprehensive check — compare every marker to baseline. Expect to see liver enzymes trending down, lipids improving, HOMA-IR decreasing, and IGF-1 elevated but within target. ### Week 12 — End of Protocol Final comprehensive panel. This is your outcome data — the before-and-after comparison that tells you exactly what the stack accomplished. If continuing beyond 12 weeks, this becomes your new baseline for the extension period. ### IGF-1 Targets IGF-1 Level Action 50-100% above baseline Optimal range — continue current tesamorelin dose 100-150% above baseline Acceptable but monitor more frequently \> 350 ng/mL Reduce tesamorelin dose to 0.5mg or move to every other day \> 400 ng/mL Stop tesamorelin immediately, recheck in 4 weeks ### Get the Full Protocol PDF The complete dosing schedule, bloodwork template, measurement log, and direct compound links — sent to your inbox. - Protocol PDF - Bloodwork template - Weekly measurement log - Direct compound links Send Me the Protocol PDF ## Safety, Side Effects, and Red Flags ### Retatrutide Side Effects GI effects are the primary tolerability concern and the reason for slow titration. From published Phase 2 data: - Nausea — 14-60% (dose dependent, worst during titration) - Diarrhea — 9-20% - Vomiting — 3-26% - Constipation — 7-16% - Heart rate increase — +5-10 bpm above baseline (class effect of GLP-1 agonists) - Dysesthesia — 8.8-20.9% (unusual tingling/altered sensation, unique to retatrutide among GLP-1 class) ### Tesamorelin Side Effects - Injection site reactions — redness, swelling, itching at injection site - Fluid retention — mild edema in the first 1-3 weeks, typically self-resolving - Joint stiffness — especially hands and wrists, related to GH-mediated fluid shifts - Hand paresthesia — tingling in fingers, can indicate carpal tunnel compression from fluid retention - Transient glucose elevation — +7-9 mg/dL fasting glucose in first weeks ### Absolute Contraindications Do NOT use this stack if any of the following apply: - Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) - Active malignancy of any type - Pregnancy or planning to become pregnant - Known hypersensitivity to either compound - Disruption of the hypothalamic-pituitary axis (head trauma, pituitary surgery, radiation) - Type 1 diabetes ### Relative Contraindications — Proceed with Caution - Type 2 diabetes — monitor glucose closely, coordinate with physician - Diabetic retinopathy — GH/IGF-1 elevation may worsen existing retinopathy - Uncontrolled hypertension — GLP-1 agonist HR increase + GH fluid retention - History of arrhythmias — heart rate increase from retatrutide requires monitoring - History of pancreatitis — GLP-1 class has rare but documented pancreatitis risk ### When to Stop Immediately Stop the protocol and seek medical attention if you experience: - Severe persistent GI symptoms (uncontrollable vomiting, inability to stay hydrated) - Chest pain, syncope, or resting heart rate consistently above 120 bpm - Severe abdominal pain radiating to the back (potential pancreatitis) - Vision changes (may indicate retinopathy progression) - Neck swelling or difficulty swallowing (thyroid concern) - Signs of allergic reaction — facial swelling, hives, difficulty breathing ## Who This Stack Is Actually For ### This Stack Is FOR You If: - You have stubborn visceral fat that hasn't responded to diet, training, and caloric restriction - You have fatty liver or elevated liver enzymes and want to address the root cause pharmacologically - You have insulin resistance or prediabetes and want aggressive metabolic improvement - You've lost muscle on GLP-1 monotherapy and want a recomposition approach instead of pure weight loss - You're a health optimizer who understands this is a research protocol, not a prescription - You train consistently (3-5x/week resistance training) and hit your protein targets (0.8-1g per pound of lean body mass) - You run bloodwork before, during, and after the protocol — no exceptions - You understand this is a research protocol with an evidence-based rationale but without a dedicated combination clinical trial ### This Stack Is NOT For You If: - You just want to drop 20 pounds quick — semaglutide or tirzepatide alone will do that - You won't do bloodwork — running tesamorelin without IGF-1 monitoring is reckless - You don't train or eat adequate protein — the anabolic signal from tesamorelin requires mechanical loading and amino acid availability to translate into lean mass preservation - You're looking for a magic bullet — this stack amplifies the work you're already doing, it doesn't replace it - You have any absolute contraindication listed above - You can't afford the full stack — compounds, bloodwork, training, and protein intake are all mandatory components, not optional add-ons ## FAQ Can you stack retatrutide with tesamorelin? What is the best peptide stack for body recomposition? How much does a retatrutide tesamorelin stack cost per month? Does retatrutide cause muscle loss? How much visceral fat does tesamorelin reduce? Can peptides help with fatty liver? What is the difference between retatrutide and tirzepatide for recomp? How long should you run a retatrutide tesamorelin cycle? What bloodwork do you need for a peptide stack? Does tesamorelin raise blood sugar? ## Citations 1. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — A Phase 2 trial. _N Engl J Med._ 2023. [PMID: 37366315](https://pubmed.ncbi.nlm.nih.gov/37366315) 2. Sanyal AJ, et al. Retatrutide and hepatic steatosis substudy. _Nat Med._ 2024. [PMID: 38858523](https://pubmed.ncbi.nlm.nih.gov/38858523) 3. Urva S, et al. Single and multiple ascending dose study of retatrutide (LY3437943). _Lancet._ 2022. [PMID: 36354040](https://pubmed.ncbi.nlm.nih.gov/36354040) 4. Falutz J, et al. Pooled Phase 3 tesamorelin data in HIV-associated lipodystrophy. _J Clin Endocrinol Metab._ 2010. [PMID: 20554713](https://pubmed.ncbi.nlm.nih.gov/20554713) 5. Makimura H, et al. Tesamorelin reduces visceral fat in obese adults without HIV. _J Clin Endocrinol Metab._ 2012. [PMID: 23015655](https://pubmed.ncbi.nlm.nih.gov/23015655) 6. Stanley TL, et al. Tesamorelin reduces hepatic fat and fibrosis in NAFLD. _Lancet HIV._ 2019. [PMID: 31611038](https://pubmed.ncbi.nlm.nih.gov/31611038) 7. Baker JV, et al. Tesamorelin IGF-1 response and dose-dependent effects. [PMID: 22869065](https://pubmed.ncbi.nlm.nih.gov/22869065) 8. Stanley TL, et al. Transient glucose effects of tesamorelin. 2014. [PMID: 25038357](https://pubmed.ncbi.nlm.nih.gov/25038357) 9. Falutz J, et al. Glucose and tesamorelin responders — VAT reduction and metabolic improvement. [PMID: 22495074](https://pubmed.ncbi.nlm.nih.gov/22495074) 10. TRIUMPH-4 Phase 3 results. Eli Lilly press release, December 2025. 11. TRANSCEND-T2D-1 Phase 3 results. Eli Lilly press release, March 2026. 12. STEP-1 DXA body composition data. Semaglutide lean tissue loss analysis. 13. Tirzepatide DXA body composition substudy data. SURMOUNT program. 14. Egrifta (tesamorelin) FDA prescribing information. Theratechnologies Inc. Approved November 2010. 15. Retatrutide LY3437943 clinical development timeline. ClinicalTrials.gov NCT05929066, NCT06163651. ## Related Guides [ ### Retatrutide Compound Profile Full compound data, mechanism, and clinical pipeline View ](/compound/retatrutide)[ ### Tesamorelin Compound Profile GH secretagogue data, dosing, and visceral fat studies View ](/compound/tesamorelin)[ ### Reconstitution Calculator Calculate concentration and dosing for any peptide vial View ](/tools/reconstitution)[ ### Bloodwork Guide What to order, where to order, how to interpret results View ](/tools/bloodwork) Disclaimer: This content is for research and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Retatrutide is an investigational drug not approved by the FDA. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy. Off-label use and use of research-grade peptides carry inherent risks. Always consult a qualified healthcare provider before starting any research protocol. BodyHackGuide does not sell, supply, or endorse the purchase of any controlled or investigational substance. Last updated: April 10, 2026 · Written by BioChonch · BodyHackGuide Research Team Share this article: [X / Twitter](https://twitter.com/intent/tweet?text=The%20Ultimate%20Shred%20Stack%20%E2%80%94%20Retatrutide%20%2B%20Tesamorelin%20Protocol&url=https%3A%2F%2Fwww.bodyhackguide.co%2Fblog%2Fultimate-shred-stack-retatrutide-tesamorelin-protocol) [ Related deep-dive comparison Retatrutide vs Tirzepatide The GLP-1 triple agonist vs dual agonist — trial data, dosing, switch protocol View ](/compare/retatrutide-vs-tirzepatide) B [BioChonch](/about)Founder & Lead Researcher Researcher and founder of BodyHackGuide. Obsessed with evidence-based biohacking, peptide science, and nootropic protocols. Every recommendation is backed by PubMed citations and real-world testing. [](https://x.com/bodyhackguide)[](https://reddit.com/r/bodyhackguide)[](https://discord.gg/Mhq5UdRYBA)| [About the author](/about) Free 2026 Peptide Cheat Sheet — 50 pages, PDF Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one. [Download Free](/guides/peptide-cheat-sheet-download?utm_source=ultimate-shred-blog) Was this page helpful? Yes No [Back to all articles](/blog) On this page [Why the Scale Lies](#why-scale-lies)[Retatrutide](#retatrutide)[Tesamorelin](#tesamorelin)[Why the Stack Works](#why-stack-works)[The Protocol](#protocol)[Recomp Calculator](#recomp-calculator)[Dosing Schedule](#dosing-schedule)[Cost Breakdown](#cost-breakdown)[Bloodwork](#bloodwork)[Safety](#safety)[Who It's For](#who-its-for)[FAQ](#faq) ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) [Shop BHG Labs · 20% off with BHG20](https://bhglabs.co/shop/?utm_source=reddit&utm_medium=paid&utm_campaign=bhg20_bridge&utm_content=sticky_mobile_bar&coupon=BHG20) hi 👋